McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI 53705.
Department of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705.
Proc Natl Acad Sci U S A. 2023 Mar 21;120(12):e2214225120. doi: 10.1073/pnas.2214225120. Epub 2023 Mar 14.
A murine papillomavirus, MmuPV1, infects both cutaneous and mucosal epithelia of laboratory mice and can be used to model high-risk human papillomavirus (HPV) infection and HPV-associated disease. We have shown that estrogen exacerbates papillomavirus-induced cervical disease in HPV-transgenic mice. We have also previously identified stress keratin 17 (K17) as a host factor that supports MmuPV1-induced cutaneous disease. Here, we sought to test the role of estrogen and K17 in MmuPV1 infection and associated disease in the female reproductive tract. We experimentally infected wild-type and K17 knockout (K17KO) mice with MmuPV1 in the female reproductive tract in the presence or absence of exogenous estrogen for 6 mon. We observed that a significantly higher percentage of K17KO mice cleared the virus as opposed to wild-type mice. In estrogen-treated wild-type mice, the MmuPV1 viral copy number was significantly higher compared to untreated mice by as early as 2 wk postinfection, suggesting that estrogen may help facilitate MmuPV1 infection and/or establishment. Consistent with this, viral clearance was not observed in either wild-type or K17KO mice when treated with estrogen. Furthermore, neoplastic disease progression and cervical carcinogenesis were supported by the presence of K17 and exacerbated by estrogen treatment. Subsequent analyses indicated that estrogen treatment induces a systemic immunosuppressive state in MmuPV1-infected animals and that both estrogen and K17 modulate the local intratumoral immune microenvironment within MmuPV1-induced neoplastic lesions. Collectively, these findings suggest that estrogen and K17 act at multiple stages of papillomavirus-induced disease at least in part via immunomodulatory mechanisms.
一种小鼠乳头瘤病毒(MmuPV1)感染实验小鼠的皮肤和黏膜上皮组织,可用于模拟高危型人乳头瘤病毒(HPV)感染和 HPV 相关疾病。我们已经表明,雌激素会加重 HPV 转基因小鼠的乳头瘤病毒引起的宫颈疾病。我们之前还确定应激角蛋白 17(K17)是一种支持 MmuPV1 引起的皮肤疾病的宿主因素。在这里,我们试图测试雌激素和 K17 在 MmuPV1 感染和雌性生殖道相关疾病中的作用。我们通过实验将 MmuPV1 感染到雌性生殖道中的野生型和 K17 敲除(K17KO)小鼠中,同时存在或不存在外源性雌激素,持续 6 个月。我们观察到,与野生型小鼠相比,K17KO 小鼠清除病毒的比例明显更高。在经雌激素处理的野生型小鼠中,MmuPV1 病毒拷贝数早在感染后 2 周就明显高于未处理的小鼠,这表明雌激素可能有助于促进 MmuPV1 感染和/或建立。与此一致的是,当用雌激素处理时,无论是野生型还是 K17KO 小鼠都没有观察到病毒清除。此外,K17 的存在支持了肿瘤疾病的进展和宫颈癌变,并受到雌激素治疗的加剧。随后的分析表明,雌激素治疗会在感染 MmuPV1 的动物中引起全身性免疫抑制状态,并且雌激素和 K17 都会调节 MmuPV1 诱导的肿瘤病变内的局部肿瘤内免疫微环境。总的来说,这些发现表明,雌激素和 K17 至少部分通过免疫调节机制在乳头瘤病毒诱导的疾病的多个阶段发挥作用。